Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging
Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently over expressed...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00466/full |
id |
doaj-84291063d67b48778800510d0f38ac7b |
---|---|
record_format |
Article |
spelling |
doaj-84291063d67b48778800510d0f38ac7b2020-11-24T21:39:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-12-01710.3389/fphar.2016.00466224205Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imagingLinda K Mooberry0Nirupama Avinash Sabnis1Bhavani Nagarajan2Marlyn Panchoo3Andras G Lacko4Andras G Lacko5University of North Texas Health Science CenterUniversity of North Texas Health Science CenterUniversity of North Texas Health Science CenterUniversity of North Texas Health Science CenterUniversity of North Texas Health Science CenterUniversity of North Texas Health Science CenterMalignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently over expressed by most tumor cells. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein (rHDL) nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00466/fullDrug Delivery Systemstumor imagingindividual therapySR-B1gateway for theranostics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Linda K Mooberry Nirupama Avinash Sabnis Bhavani Nagarajan Marlyn Panchoo Andras G Lacko Andras G Lacko |
spellingShingle |
Linda K Mooberry Nirupama Avinash Sabnis Bhavani Nagarajan Marlyn Panchoo Andras G Lacko Andras G Lacko Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging Frontiers in Pharmacology Drug Delivery Systems tumor imaging individual therapy SR-B1 gateway for theranostics |
author_facet |
Linda K Mooberry Nirupama Avinash Sabnis Bhavani Nagarajan Marlyn Panchoo Andras G Lacko Andras G Lacko |
author_sort |
Linda K Mooberry |
title |
Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging |
title_short |
Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging |
title_full |
Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging |
title_fullStr |
Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging |
title_full_unstemmed |
Targeting the SR-B1 receptor as a gateway for cancer therapy and tumor imaging |
title_sort |
targeting the sr-b1 receptor as a gateway for cancer therapy and tumor imaging |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2016-12-01 |
description |
Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently over expressed by most tumor cells. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein (rHDL) nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed. |
topic |
Drug Delivery Systems tumor imaging individual therapy SR-B1 gateway for theranostics |
url |
http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00466/full |
work_keys_str_mv |
AT lindakmooberry targetingthesrb1receptorasagatewayforcancertherapyandtumorimaging AT nirupamaavinashsabnis targetingthesrb1receptorasagatewayforcancertherapyandtumorimaging AT bhavaninagarajan targetingthesrb1receptorasagatewayforcancertherapyandtumorimaging AT marlynpanchoo targetingthesrb1receptorasagatewayforcancertherapyandtumorimaging AT andrasglacko targetingthesrb1receptorasagatewayforcancertherapyandtumorimaging AT andrasglacko targetingthesrb1receptorasagatewayforcancertherapyandtumorimaging |
_version_ |
1725929886254628864 |